Navigation Links
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
Date:3/6/2008

SAN DIEGO, March 6 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its fourth quarter and full year ended December 31, 2007 financial results after the close of market on Wednesday, March 12, 2008.

Cadence management will host a conference call and live webcast to discuss the financial results and provide a corporate overview on Wednesday, March 12, 2008 at 1:30 pm Pacific Time (4:30 pm Eastern Time). Interested investors may participate in the conference call by dialing 877-681-3375 (domestic) or 719-325-4913 (international). To access the webcast, please visit the company's website at http://www.cadencepharm.com and go to the Investor Relations page. A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, including intravenous acetaminophen (IV acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% aqueous gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com.

Cadence(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.

Contacts: William R. LaRue

SVP & Chief Financial Officer

Cadence Pharmaceuticals, Inc.

858-436-1400

Anna Gralinska

Director, Investor Relations

Cadence Pharmaceuticals, Inc.

858-436-1452


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
2. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
4. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007
6. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIO Investor Forum
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference
8. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
11. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" ... Liver Congress ("ILC") 2017 of the European Association for the ... on the positive effects of PBI-4050 on reduction of ... metabolic syndrome. ... Dr. Lyne Gagnon, Vice-President of R&D Pre-clinical of Prometic "This ...
(Date:4/20/2017)... ... April 20, 2017 , ... Open Therapeutics and the ... sharing and commercialization model. , The Center for Advancing Innovation helps institutions maximize ... effort is bringing the IP to the attention of the entrepreneurial community and ...
(Date:4/20/2017)... April 20, 2017 For today, Stock-Callers.com ... novel drug development and clinical research aimed at treating diseases ... (NASDAQ: BSTG), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Kite Pharma Inc. ... ). You can access our complimentary research reports on these ... ...
(Date:4/19/2017)... ... April 18, 2017 , ... Alisa Wright, founder and CEO ... from the Purdue College of Pharmacy in Lafayette, Indiana. , The Distinguished Alumni ... achievements in their careers and other scientific endeavors. , Wright began her career ...
Breaking Biology Technology:
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University (PolyU) ... ground breaking 3D fingerprint minutiae recovery and matching technology, pushing contactless ... use in identification, crime investigation, immigration control, security of access and ... ... A research team led by Dr Ajay Kumar ...
Breaking Biology News(10 mins):